Bridge Biotec Limited (“Bridge”) is developing novel therapeutics to safely treat life threatening and disabling inflammatory conditions such as inflammatory bowel disease (IBD), atopic dermatitis (AD, eczema), psoriasis and burns to cure serious inflammatory diseases.
Inflammation refers to a biological response to stimuli, interpreted by the body to have a potentially harmful effect. In certain situations, such as after injury, inflammation is a normal response. However, inflammatory diseases result in the immune system attacking the body’s own cells or tissues and may cause abnormal inflammation resulting in chronic pain, swelling, stiffness and damage to normal tissues.
Bridge Biotec’s novel medicines are short proteins (“peptides”) that can be delivered into the human cell using a patented safe nano-polymer delivery technology which have been shown to switch off inflammation in a recognised cellular model. These short peptides, that will be broken down into simple and naturally occurring amino acids, are highly active and exquisitely specific inflammation blockers, so only tiny doses will be required to cure serious inflammatory diseases.
Bridge is an ambitious company aiming to be revenue-generating within 18 months.
If you would like to make a donation to Bridge Biotec to help us advance our research into inflammation treatments, please use the donate button below.